<DOC>
	<DOCNO>NCT01743365</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination Cisplatin,5-Fluorouracil ( 5FU ) Afatinib first-line therapy patient advance gastric gastroesophageal junction cancer . The study include 55 patient . The patient receive open-label Cisplatin intravenous 75mg/m2 Day 1 , 5FU 750mg/m2 24-hour intravenous infusion Days 1-4 , Afatinib 40mg per os Days 3-5 , 8-12 , 15-19 . The administration Afatinib start Day 3 therapy cycle administration interval weekend ( `` Weekday , Weekend '' ) 21 day . Instructions give dose reduction scheme presence toxicity . The administration combination Cisplatin-5FU-Afatinib continue disease progression , appearance significant toxicity , completion 6 treatment cycle , withdrawal consent . At completion 6 cycle combination , absence disease progression , administration Afatinib maintenance monotherapy continue disease progression , appearance significant toxicity , withdrawal consent weekday on-weekend schedule . Imaging apply every 8 week , every 12 week Afatinib maintenance therapy phase .</brief_summary>
	<brief_title>Clinical Trial Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib Patients With Inoperable Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients histological cytological diagnosis gastric and/or gastroesophageal junction adenocarcinoma/carcinoma . Locally advanced metastatic inoperable disease . Life expectancy ≥12 week . Patients may undergo type palliative treatment localise disease , include surgical approach palliative radiotherapy , last four week trial . Adequate bone marrow , hepatic renal functional reserve ( ANC≥1500mm3 , PLT≥100mm3 , GFR≥50ml/min Gault Formula , bilirubin &lt; 1.5x , Aspartate Aminotransferase ( AST ) /Alanine Aminotransferase ( ALT ) &lt; 2.5x upper normal limit 5x presence hepatic metastasis ) . Patients must able swallow pharmaceutical tablet eligible receive intravenous chemotherapy . Men woman patient must least 18 year old . Performance Status Scale 0 1 ( ECOG ) . Measurable disease accord RECIST 1.1 . Left ventricular ejection fraction ( LVEF ) ≥50 % ( ECHO MUGA ) . Provision patient inform consent participation study use biological material research purpose . Willingness ability comply schedule medical visit , therapeutic treatment programme , laboratory test study procedure . Previous systemic firstline therapy . Previous therapy EGFR/HER Tyrosine Kinase Inhibitor ( TKI ) experimental agent . Diagnosis second malignancy , except basal cell carcinoma squamous epithelium situ carcinoma organ , appropriate treatment administer without indication relapse 12 month . Presence uncontrolled , active brain metastasis ( control brain metastasis consider irradiated remain stable least 4 week radiation therapy ) . Diagnosis spinal cord compression carcinomatous meningitis . Any following occur within 12 month start study treatment : myocardial infarction , serious unstable angina pectoris , aorticcoronary peripheral bypass surgery , symptomatic heart failure , vascular stroke , transient ischemic attack , pulmonary embolism . Continuing grade ≥2 heart rate abnormality ; atrial fibrillation grade . Hypertension uncontrolled medication treatment ( &gt; 150/100 mm/Hg despite administration best medical therapy ) . In case previous irradiation locally advanced disease , absence measurable tumor site outside irradiation field . Presence disease opinion doctor responsible constitutes contraindication administration cisplatin , 5FU afatinib . Diagnosed human immunodeficiency virus ( HIV ) disease associate Acquired Immunodeficiency Syndrome ( AIDS ) . Pregnancy lactation . Female patient must surgically sterilise , menopausal , must consent use effective contraception throughout course trial.All female patient reproduction ability must undergo pregnancy test ( serum urine ) . The effective contraceptive technique determine main investigator person authorize investigator . Any serious , acute chronic , medical psychiatric condition laboratory analysis finding , investigator 's opinion , could create excessive danger regard patient 's participation trial administration trial medication may render patient ineligible inclusion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>